Bicara Therapeutics Announces Pricing for Enhanced Initial Public Offering Via Investing.com
BOSTON, Sept. 12, 2024 (GLOBE NEWSWIRE) — Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing two revolutionary therapies to patients with solid tumors, today announced the price of its initial public offering. 17,500,000 shares of its common stock at a public offering price of $18.00 per share. Bicara Therapeutics shares are expected to begin trading on the Nasdaq Global Market on September 13, 2024 under the ticker symbol BCAX. The offering is expected to close on September 16, 2024, subject to the satisfaction of customary closing conditions. In addition, Bicara Therapeutics has granted the underwriters a 30-day option to purchase an additional 2,625,000 shares of its common stock at the public offering price, less discounts and commissions. All shares of common stock are offered by Bicara Therapeutics.
Morgan Stanley TD Cowen, Cantor and Stifel are acting as joint bookrunners for the offering.
The gross proceeds of Bicara Therapeutics from the initial public offering, before deducting underwriting discounts and commissions and other offering expenses paid to Bicara Therapeutics, are expected to be approximately $315.00 million, excluding any exercise of the underwriters' option to purchase additional shares of common stock. .
The registration statement relating to the shares sold in the initial public offering has been filed with the Securities and Exchange Commission and has been declared effective on September 12, 2024. The offering is made only by prospectus. A copy of the final prospectus, when available, can be obtained from: Morgan Stanley & Co (NYSE: LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, by telephone at (866) 718-1649, or by email at prospectus@morganstanley.com; TD Securities (USA) LLC, 1 Vanderbilt Avenue, New York, New York 10017, by telephone at (855) 495-9846, or by email at TD.ECM_Prospectus@tdsecurities.com; Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59th Street, 6th Floor, New York, New York 10022 or by email at prospectus@cantor.com; or Stifel, Nicolaus & Company, Incorporated, Attention: Prospectus Department, One Montgomery Street, Suite 3700, San Francisco, CA 94104 by telephone at (415) 364-2720 or by email at syndprospectus@stifel.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction where such offer, solicitation or sale would be lawful prior to registration or qualification under the securities laws of any such state or jurisdiction. .
About Bicara Therapeutics
Bicara Therapeutics is a clinical-stage biopharmaceutical company committed to bringing novel therapeutics to patients with solid tumors. Bicara's lead product, ficerafusp alfa, is a bi-functional antibody that combines two clinically proven targets, the epidermal growth factor receptor (EGFR) targeting monoclonal antibody with a binding domain to human transforming growth factor beta (TGF-β) . Through this dual-targeting approach, ficerafusp alfa has the potential to exert powerful anti-tumor activity by simultaneously inhibiting both the survival and proliferation of cancer cell EGFR, as well as TGF-β signaling that protects the immune system within the tumor microenvironment. Ficerafusp alfa is initially being developed in head and neck squamous cell carcinoma, where there is still significant unmet need.
Cautionary Note Regarding Forward-Looking Statements
This press release contains certain disclosures that contain forward-looking statements, including, without limitation, statements regarding Bicara Therapeutics' expectations regarding the commencement of trading of its shares on the Nasdaq Global Market, the completion and timing of the closing of the offering and the expected gross proceeds from the offering. Forward-looking statements are based on Bicara Therapeutics' current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to the satisfaction of customary closing conditions and completion of the offering, as well as risks inherent in biopharmaceutical product development and clinical trials. These and other risks and uncertainties are more fully described in the section entitled Risk Factors of the registration statement filed with the Securities and Exchange Commission. The forward-looking statements contained in this announcement are made as of the date hereof, and Bicara Therapeutics undertakes no obligation to update such information except as required by applicable law. Readers should not rely on the information on this page as current or accurate after its publication date.
Contacts
Investors
Rachel Frank
ir@bicara.com
Media
Dan Budwick
1AB
dan@1abmedia.com
Source: Bicara Therapeutics Inc.
